Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$69.00 USD

69.00
3,405,133

-0.70 (-1.00%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks News

Intuitive Surgical (ISRG) Q4 Earnings Top, Margins Expand

Intuitive Surgical (ISRG) gains from solid international show in Q4.

NextGen (NXGN) Earnings and Revenues Beat Estimates in Q3

NextGen (NXGN) gains from Recurring revenues in Q3, bookings down.

Neena Mishra headshot

Best Thematic ETFs for 2020: Cloud, Internet of Things & More

Find out more about cloud computing, Internet of Things, video games and infrastructure ETFs.

Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?

Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.

Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?

Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.

What's in Store for Varian Medical (VAR) in Q1 Earnings?

Demand for Eclipse and TrueBeam is expected to have driven Varian's (VAR) Oncology revenues in fiscal Q1.

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine are likely to have contributed to Stryker's (SYK) Q4 earnings.

Here's Why You Should Add DexCom (DXCM) to Your Portfolio

DexCom (DXCM) expects its strong product portfolio to consistently drive top line.

Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now

Veeva (VEEV) sees a slew of positive developments.

Here's Why DexCom (DXCM) is a Great Momentum Stock to Buy

Does DexCom (DXCM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?

Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sriparna Ghosal headshot

Diabetes Management Gains FDA Attention: 3 Stocks in Focus

The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.

Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results

Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.

Allscripts Expands Partnership With PIH Health Through 2025

Encouraged by its solid EHR prospects, Allscripts (MDRX) expects a surge in its fourth-quarter 2019 bookings.

Inogen (INGN) Announces Preliminary Q4 Results, Slashes View

Inogen (INGN) expects direct-to-consumer sales to be its fastest-growing channel in 2020.

DexCom (DXCM) Dips More Than Broader Markets: What You Should Know

DexCom (DXCM) closed the most recent trading day at $235.06, moving -0.33% from the previous trading session.

ABIOMED (ABMD) Announces Preliminary Q3 Results, Slashes View

ABIOMED's (ABMD) Q3 international revenues grew year over year; fiscal 2020 view slashed.

Here's Why You Should Add Cerner (CERN) to Your Portfolio

Cerner (CERN) expects revenues between $1.41 billion and $1.46 billion in the fourth quarter.

Here's Why You Should Hold on to AngioDynamics Stock Now

AngioDynamics (ANGO) retains fiscal 2020 view; VA revenues soft in fiscal Q2.

DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know

DexCom (DXCM) closed at $233.23 in the latest trading session, marking a +0.77% move from the prior day.

Walgreens Boots (WBA) Q1 Earnings Lag Estimates, Margins Fall

Sluggishness in Walgreens Boots' (WBA) Retail Pharmacy International segment and margin contractions put pressure on the bottom line during Q1.

Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?

Is (DXCM) Outperforming Other Medical Stocks This Year?

DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

AngioDynamics (ANGO) Q2 Earnings Top, Revenues Lag Estimates

AngioDynamics (ANGO) gains from core Oncology business in the fiscal second quarter, reiterates guidance.

Here's Why You Should Hold on to Becton, Dickinson Stock Now

Becton, Dickinson (BDX) expects fiscal 2020 revenue growth to be driven by recent product launches.